A role for the NMDA positive modulator NYX-783 in preclinical opioid use disorder research
Positive allosteric modulator of the NMDA receptor, NYX-783, reverses repeated stress-induced reduction of exploration and reduces fear to unpredictable threats in rats
NYX-783, a Novel Positive Allosteric Modulator of N-methyl-D-Aspartate Receptor, Facilitates Extinction Learnings in PTSD-Relevant Mouse Models
Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear
The Novel NMDAR Modulator NYX-783 Facilitates Extinction of Ethanol-seeking Behavior and Blocks Relapse-like Behavior Primed by Ethanol-associated Cues or Prior Stress in Rats
The Novel N-Methyl-D-aspartate Receptor Modulator NYX-783 Exhibits Therapeutic Effects in Rodent Models Useful for the Study of Post-Traumatic Stress Disorder and Comorbid Alcohol Use Disorder
NYX-783, a novel NMDAR modulator, rescues the detrimental effects of encephalitis-causing anti-NMDAR antibodies on GluN2B-NMDAR expression in vitro
A Novel NMDA Receptor Modulator, NYX-783, Shows Therapeutic Potential as a Treatment for PTSD and TBI
NYX-783 is a Novel NMDA Receptor Modulator with Therapeutic Potential for the Treatment of Post-Traumatic Stress Disorder (PTSD)
NYX-458 Improves Cognitive Performance in a Primate Parkinson’s Disease Model
NYX-458, a novel NMDA receptor modulator, improves age-related, hippocampal-dependent learning impairment and reverses changes in plasticity, spine morphology, and protein expression in rat hippocampus
NMDA Receptor Modulation with NYX-458 Rescues Cognitive Impairment and Peripheral Growth Hormone Levels in a Clinically Relevant Model of Repeat Concussion
A Novel NMDA Receptor Modulator, NYX-458, Shows Therapeutic Potential for Cognitive Impairment Associated with TBI in Rats
The NMDAR Modulator NYX-458 Does Not Worsen Motor Symptoms or Interfere with L-DOPA’s Anti-Parkinsonian Effect in a Non-human Primate Parkinson’s Disease Model
The NMDA Receptor Modulator NYX-458 Results in Long-lasting Improvement in Several Cognitive Domains in a Primate Model of Parkinson’s Disease Cognitive Impairement
NYX-458, a NMDA Receptor Modulator, Improves Cognitive Deficits in a Non-Human Primate MPTP Model Of Cognitive Impairment In Parkinson’s Disease
NYX-458, a NMDA receptor modulator, when tested in aged F344 rats, facilitates LTP and reverses age-related cognitive deficits as measured by the Morris water maze
NYX-458, a novel small molecule NMDA receptor modulator, enhances novel object recognition in rats
